A Shannon, V Fattorini, B Sama, B Selisko… - Nature …, 2022 - ideas.repec.org
The guanosine analog AT-527 represents a promising candidate against Severe Acute Respiratory Syndrome coronavirus type 2 (SARS-CoV-2). AT-527 recently entered phase III …
A Shannon, V Fattorini, B Sama, B Selisko, M Feracci… - 2022 - agris.fao.org
English. The guanosine analog AT-527 represents a promising candidate against Severe Acute Respiratory Syndrome coronavirus type 2 (SARS-CoV-2). AT-527 recently entered …
A Shannon, V Fattorini, B Sama, B Selisko… - Nature …, 2022 - ncbi.nlm.nih.gov
The guanosine analog AT-527 represents a promising candidate against Severe Acute Respiratory Syndrome coronavirus type 2 (SARS-CoV-2). AT-527 recently entered phase III …
A Shannon, V Fattorini, B Sama… - Nature …, 2022 - pubmed.ncbi.nlm.nih.gov
The guanosine analog AT-527 represents a promising candidate against Severe Acute Respiratory Syndrome coronavirus type 2 (SARS-CoV-2). AT-527 recently entered phase III …
A Shannon, V Fattorini, B Sama… - Nature …, 2022 - search.ebscohost.com
The guanosine analog AT-527 represents a promising candidate against Severe Acute Respiratory Syndrome coronavirus type 2 (SARS-CoV-2). AT-527 recently entered phase III …
A Shannon, V Fattorini, B Sama… - Nature …, 2022 - econpapers.repec.org
The guanosine analog AT-527 represents a promising candidate against Severe Acute Respiratory Syndrome coronavirus type 2 (SARS-CoV-2). AT-527 recently entered phase III …
A Shannon, V Fattorini, B Sama… - Nature …, 2022 - ui.adsabs.harvard.edu
The guanosine analog AT-527 represents a promising candidate against Severe Acute Respiratory Syndrome coronavirus type 2 (SARS-CoV-2). AT-527 recently entered phase III …
A Shannon, V Fattorini, B Sama, B Selisko… - Nature …, 2022 - hal.science
The guanosine analog AT-527 represents a promising candidate against Severe Acute Respiratory Syndrome coronavirus type 2 (SARS-CoV-2). AT-527 recently entered phase III …
A Shannon, V Fattorini, B Sama, B Selisko… - Nature …, 2022 - europepmc.org
The guanosine analog AT-527 represents a promising candidate against Severe Acute Respiratory Syndrome coronavirus type 2 (SARS-CoV-2). AT-527 recently entered phase III …